🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

29 recruiting trials

for High-risk NMIBC

Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer NCT07646145Phase 21 site📍 Taiyuan Shanxi Province Cancer Hospital · Tests: Disitamab Vedotin, Mitomycin C (MMC) The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy NCT06388720Phase 21 site📍 Goyang-si National Cancer Center, Korea · Tests: Mitomycin-C, gemcitabine The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection NCT06287541NA1 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Urine biomarker -Guided without reTURBT LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve NCT04752722Phase 1, Phase 2102 sites📍 Birmingham📍 Scottsdale📍 Tucson enGene, Inc. · Tests: EG-70 (phase 1), EG-70 (phase 2) Master Protocol, Surfactant Bladder Pre-Rinse and EG-70 (Substudy) Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy NCT07000084Phase 360 sites📍 Birmingham📍 Fairbanks📍 Gilbert Alliance for Clinical Trials in Oncology · Tests: BCG Solution, Biopsy of Bladder, Cystoscopy, Computed Tomography, Magnetic Resonance Imaging A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC) NCT06108492Phase 11 site📍 Shanghai Shanghai Hengrui Pharmaceutical Co., Ltd. · Tests: SHR-2005 Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC) NCT05825950n/a2 sites📍 Dallas📍 San Antonio University of Texas Southwestern Medical Center Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC) NCT07763197n/a1 site📍 Austin Natera, Inc. Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC? NCT07625527Phase 24 sites📍 Tianjin📍 Tianjin📍 Tianjin Tianjin Medical University Second Hospital · Tests: Active Surveillance, PD-1/PD-L1 Inhibitor-Based Systemic Immunotherapy Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC NCT07322263Phase 21 site📍 Iowa City Michael A. O'Donnell · Tests: Intravesical Gemcitabine and Docetaxel Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients NCT06696794Phase 33 sites📍 Wuhan📍 Wuhan📍 Xiangyang Shaogang Wang · Tests: Mitomycin C (MMC), Normal Saline (Placebo) Toripalimab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration NCT07307456Phase 21 site📍 Shanghai Changhai Hospital · Tests: Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor (TURBT) Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) NCT05037279Phase 36 sites📍 Vancouver📍 Kingston📍 Toronto Verity Pharmaceuticals Inc. · Tests: Bacillus Calmette-Guerin: Strain Russian BCG-I, Bacillus Calmette-Guerin: Strain TICE To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2 NCT06378242Phase 1, Phase 26 sites📍 Guangzhou📍 Wuhan📍 Changsha RemeGen Co., Ltd. · Tests: Disitamab Vedotin for injection A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing NCT07036731NA1 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Urine biomarker -Guided without reTURBT A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC NCT05410730Phase 1, Phase 21 site📍 Beijing Shanghai Hengrui Pharmaceutical Co., Ltd. · Tests: SHR-1501 Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC NCT06567743Phase 280 sites📍 Gilbert📍 Phoenix📍 Tucson CG Oncology, Inc. · Tests: Cretostimogene Grenadenorepvec A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC NCT06971614Phase 29 sites📍 Queen Creek📍 Los Angeles📍 Orlando ImmVira Pharma Co. Ltd · Tests: T3011 A Study to Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in Portugal NCT07784387n/a1 site📍 Lisbon Janssen-Cilag Farmaceutica Ltda. A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC NCT07726992Phase 32 sites📍 Beijing📍 Guangzhou Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Tests: SHR-1501+BCG, Placebo +BCG RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects NCT05943379Phase 21 site📍 Beijing RemeGen Co., Ltd. · Tests: RC48-ADC in Combination with gemcitabine Prognostic Effect of Whether Doing PLND During RC for High-risk NMIBC NCT05123625NA1 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Reduce surgical procedures Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy NCT06972615Phase 21 site📍 CABA BLATAM · Tests: intravesical Chemotherapy docetaxel/gemcitabine A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer NCT06545955Phase 380 sites📍 Tucson📍 Little Rock📍 Los Angeles Ferring Pharmaceuticals · Tests: Nadofaragene Firadenovec, Gemcitabine, Docetaxel, Pembrolizumab Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer NCT05951179Phase 278 sites📍 Homewood📍 Phoenix📍 Queen Creek Protara Therapeutics · Tests: TARA-002 DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC NCT07207824Phase 31 site📍 Shanghai Fudan University · Tests: Active Comparator: BCG induction and maintenance, DV + BCG induction and maintenance The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer NCT07130578n/a2 sites📍 Tianjin📍 Tianjin Tianjin Medical University Second Hospital · Tests: urine tumor DNA/RNA testing Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer NCT06889623NA1 site📍 Shanghai Changhai Hospital · Tests: Immediate postoperative chemotherapy A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD) NCT06991868n/a1 site📍 Beijing Peking University First Hospital
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy